Introduction
Osteoporosis and atherosclerosis are leading causes of morbidity and mortality in the Western world. Although these conditions commonly co-occur in older adults, growing evidence suggests an association between vascular calcification and skeletal fragility that is independent of age and other shared risk factors. Older adults with the greatest bone loss have the greatest progression of vascular calcification 1, 2 and the incidence of cardiovascular (CV) events is greater in women with lower bone mass 3 and in men with higher levels of bone resorption 4, 5 . The association between both pathologies also depends on the mechanisms involved in the regulation of bone and CV metabolism 5 . We have previously shown that the nutrients and micronutrients that benefit the CV system generally also benefit bone [6] [7] [8] . In this article we discuss the effect and interactions of the principal dietary bone minerals (calcium, phosphorus, magnesium) and vitamin D on CV calcification and bone health in principally older adults. Where these studies also investigated other aspects of CV health, we report these as well. Although other minerals, such as potassium, sodium, selenium and zinc are known to be involved in bone health, there are no human or animal studies investigating their association with CV calcification, so we have not included them. We have taken an effect on bone to mean an effect on at least one skeletal site but not necessarily all sites.
Calcium
Calcium fulfils vital roles in the body, particularly with respect to cell signalling functions; for this reason it is critical that serum calcium be maintained in a very narrow range. There are two modes of intestinal calcium absorption: active transcellular absorption, mediated by 1,25(OH)2D binding to the intestinal vitamin D receptor (VDR), and passive paracellular absorption, dependent on the calcium gradient, with high intake stimulating increased absorption independent of 1,25(OH)2D 9, 10 . Active calcium absorption decreases when serum 25(OH) D concentration is <20nmol/L and consequently low calcium intake aggravates the consequences of vitamin D deficiency 9 . 1,25(OH)2D also increases renal reabsorption of calcium and upregulates bone resorption by facilitating osteoclast maturation, thereby increasing serum calcium 11 . Animal studies demonstrate that maintaining normocalcaemia takes priority over skeletal integrity because of calcium's multiple intracellular and extracellular roles 12 . Dietary sources of calcium are mainly dairy products, fish, legumes, grains and vegetables 13, 14 .
CV calcification
Observational studies generally show little association of calcium intake, dietary or supplemental, with coronary artery calcification (CAC) or abdominal aortic calcification (AAC) incidence or extent in older adults 4, [15] [16] [17] [18] , although a large study showed that calcium intake was significantly higher in postmenopausal men and women without AAC at baseline and in women only after five years 19 . Koreans with the highest calcium intake (>840mg/d) also had improved serum lipid profiles 20 . Many studies of serum calcium show no association with calcification [21] [22] [23] [24] [25] , although some show a positive correlation with presence, extent and progression of AAC in older adults 19, [26] [27] , with mixed results for presence of CAC, although there may be an association with extent or progression [18] [19] [28] [29] . Serum calcium was an independent predictor of calcified and mixed plaque but not non-calcified plaque 29 and higher concentrations were associated with lower in-hospital mortality among MI patients 30 . Nevertheless, serum calcium levels often bear little relationship to intake, as is evidenced by the study by Wang et al, where higher serum calcium was associated with increased AAC but a higher calcium intake was found in those with no AAC 19 . Nunes has suggested that it is the deranged metabolism of calcium and phosphorus, rather than the intake, which may be promoting CV calcification, particularly in CKD 31 . Animal studies have shown that low calcium intake induces higher nephrocalcinosis and aortic calcium content, while high calcium intake is not generally associated with calcification in health [32] [33] [34] but in rats with chronic kidney disease (CKD) and secondary hyperparathyroidism calcium supplementation increased arterial calcification 35 .
In view of the recent concern by Bolland et al that elevated serum calcium or calcium supplementation, but not dietary calcium, might increase CV events [36] [37] [38] , a review and subsequent studies found no evidence of any significant effect of calcium supplementation on the risk of coronary artery disease (CAD), stroke, CVD events 15, 17, 39 . In fact, a systematic review showed a strong association between calcium malnutrition and risk of hypertension and CV events 40 , while 1g/d calcium supplementation was associated with lower CVD and CHD risk after four years 41 and reduced mortality in women after 10 years 42 , with calcium supplementation protecting against vascular disease by lowering serum cholesterol level and blood pressure [43] [44] .
Bone
Although osteoporosis appears to have little association with serum calcium 45 , a review of observational studies found an association of low calcium intake and osteoporosis risk 40 , with an intake threshold of <400mg/d 46 . This may only be a shortterm association, possibly suggesting adaptation to a low calcium intake 47 . As with CV calcification, several recent metaanalyses and systematic reviews of studies of healthy adults have concluded that the evidence for an association between calcium intake and BMD or fracture risk was insufficiently clear [48] [49] [50] [51] , although a Cochrane Review and recent studies have shown an effect of calcium supplementation on BMD but not fracture incidence in postmenopausal women, with an effective mean intake being >800mg/d 17, [52] [53] , although much higher intakes have reduced fracture risk in other studies 17, [54] [55] .
Postmenopausal women possibly require a total intake of >1100mg/d [56] [57] [58] , although calcium may only be effective in the first five postmenopausal years 59 . Some of the inconsistent results may be due to the fact that few studies measure baseline calcium intake or status; supplementation in replete subjects is unlikely to have a benefit 9 . Furthermore, race may account for some of the mixed results; among postmenopausal women, there was a positive association between BMD and calcium intake in white but not Hispanic, black or MexicanAmerican women 60 , whereas among older men there was a correlation between BMD and calcium intake in blacks but not whites 61 . Where calcium intake has been found predictive of BMD, the necessary intake for bone health appears to be >800 mg/day.
Phosphorus
Phosphate is critical for bone mineralisation but also for cell signalling and energy storage in the form of ATP, requiring strict control over blood concentrations, as with calcium 62 .
The main dietary sources of organic phosphorus are animal and plant proteins 63 , while inorganic phosphorus is mostly seen in food preservatives or as phosphoric acid in colas; phosphoric acid may also bind with calcium in the intestine, so preventing calcium absorption 64 . Although up to 100% of inorganic phosphorus may be absorbed, only 40-60% of organic phosphorus is absorbed. Furthermore, much of plant phosphorus is in the form of phytate (myo-inositol hexakisphosphate), found principally in unrefined cereals and legumes, which can inhibit absorption of several minerals by forming non-digestible mineral complexes [65] [66] . As with calcium, there are two mechanisms of phosphorus absorption: an active 1,25(OH)2D-dependent process, utilising sodium phosphate cotransporters, and a passive diffusional process dependent on the phosphorus gradient 62, [66] [67] [68] [69] . Phosphorus restriction can also increase synthesis of 1,25(OH)2D 70 . There are growing concerns that excess phosphorus intake from food additives and colas, with concomitant decrease in calcium intake from vegetables, in the general population may be a risk factor for CV disease, osteoporosis and mortality, possibly through induction of secondary hyperparathyroidism, even when serum phosphate remains within the normal range 71 .
CV calcification
In the few studies of the effect of dietary phosphorus on human CV calcification there is no association in older Koreans 18 , although animal studies show a positive association between phosphorus intake and aortic and renal calcification and atheroma incidence [71] [72] . found a significant association between baseline mean serum phosphate levels (>1.292mmol/l vs ≤0.969mmol/l) and baseline aortic valve calcification (AVC), mitral annulus calcification (MAC) and AAC presence but not with extent, progression or new development after a mean of 2.4 years; the association with AAC lost significance after adjustment 25, 73 . These studies demonstrate that even a serum phosphate value within the reference range (0.8-1.4mmol/l) is associated with CV calcification, as well as increased CV risk [66] . Studies of older adults and CKD patients also found a significant association between higher serum phosphate and presence and extent of calcification 18, 21, 22, 26, 28, 29 , with each 0.0323mmol/l rise in serum phosphorus being associated with 6.1% higher odds of having CAC 21 . Wang et al found a gender difference; in postmenopausal women, serum phosphate was significantly higher (1.15 vs 1.17 mmol/l) in subjects with AAC, while in older men there was no association 19 . Elevated serum phosphate was also associated with coronary obstructive lesions and CV events, although results for mortality were mixed 21, [74] [75] . A similar association with arterial and valvular calcification and increased carotid intima/media thickness (cIMT) is generally seen in CKD, although the serum phosphate levels tend to be considerably higher 23, [76] [77] [78] [79] and are due to failure to excrete excess phosphate, which may be the driver for ectopic calcification 80 . In CKD, arterial calcification can be suppressed by reducing serum phosphate levels, even in the presence of high serum calcium and 1,25-dihydroxyvitamin D levels 81 . CKD rats showed phosphorus intake-dependent increases in markers of inflammation and oxidative stress as well as CV calcification and mortality 82 , while VSMCs cultured in normal levels of phosphorus do not calcify 79 but high inorganic phosphorus can induce calcification, endothelial dysfunction and increased markers of inflammation 21, 79, 82, 83 .
Bone
Results of adult human studies show mixed results for associations between total phosphorus intake and osteoporosis or fractures [84] [85] [86] , although inorganic phosphorus intake from colas induced a higher incidence of osteopenia and lower BMD among women only; since this was not seen with other soft drinks it is likely to be attributable to phosphoric acid 64 . Among healthy women, dietary and serum phosphorus were generally not associated with BMD or markers of bone formation or resorption 45, 85, 87 . Phosphorus supplementation in young women resulted in decreased markers of bone formation and increased markers of resorption 88 but had no adverse effect on young men 89 . A further intervention study found that the adverse effects of high phosphorus supplementation could be negated by high calcium supplementation 90 . Animal studies show that diets creating either a phosphorus excess or deficiency lower BMD and bone mineralisation 71, 91 .
Magnesium
Magnesium is an essential mineral, acting as cofactor in more than 300 enzymatic reactions. It is a natural calcium channel blocker and plays an important role in CV, neurological and metabolic functions, although approximately 60% of body magnesium is found in bone 92 . Dietary sources include legumes, vegetables, nuts, seeds, fruits, grains, fish and dairy foods 93 . As with calcium and phosphorus, there is a vitamin D-dependent intestinal absorption and gradient-driven absorption 94 .
Ectopic calcification
The principal intake study found that CV calcification was lowest in the quartile with intake ranging from 384-669mg/d 95 , while higher intake was inversely associated with stroke risk 39 , diabetes incidence and hypertension 96 . The only studies of blood concentrations involve dialysis patients and show a clear association between lower serum magnesium (1.1056mmol/l vs 1.241mmol/l) and peripheral artery calcification [97] [98] and MAC 99 , the protective amount being above the reference range (upper limit 1.2mmol/l), although this should not be extrapolated to non-renal patients. Serum magnesium was also inversely correlated with cIMT and aortic pulse wave velocity in renal and non-renal patients 100 . In animals, a low magnesium diet increased cardiac magnesium and calcium deposition 72,100-102 but the CV and renal calcification was worse when low magnesium intake was combined with high phosphorus [102] [103] . Experimental magnesium deficiency also induced arterial damage, hypertriglyceridaemia and a decrease in HDL cholesterol transport 104 . A high magnesium intake, however, was associated with a reduction in plasma cholesterol and triglycerides in rats 105 . There are no trials of magnesium supplementation on CV calcification in humans but in renal patients supplementation resulted in significantly lower cIMT 106 , while in animals supplementation dose-dependently lowered myocardial, carotid and aortic calcium content 107, 108 . Similarly, in vitro studies showed that increasing magnesium concentration reduced calcification in VSMC 83, 100 .
Bone
Dietary and serum, but not red cell, magnesium were generally lower among the elderly with osteoporosis 45, 86, 109 and among healthy older adults, magnesium intake was positively associated with BMD, BMC and bone mass 86, [110] [111] , with an intake of >422.5mg/d vs <206.5 mg/d improving BMD 110 . A large multiethnic study found that this association may apply to older whites but not blacks 112 . Some studies also found an association with BMD in younger women [113] [114] . Study results are mixed with respect to intake and fracture risk 84, 110, 115 and among Japanese subjects low serum magnesium was associated with increased fracture incidence 116 . Short term intervention studies Mechanism by which high serum phosphate (P) impacts the parathyroid gland and kidney to lower serum P
show that 1830mg/d magnesium citrate significantly decreased levels of urinary deoxypyridinoline (a marker of bone resorption) in postmenopausal osteoporotic women with normal baseline serum magnesium and calcium, while concentrations of serum osteocalcin (a marker of bone turnover) were increased 117 but there was no effect in young women 118 . Longer studies of postmenopausal women with low BMD showed that magnesium supplementation increased BMD [119] [120] .
Vitamin D
Vitamin D is a steroid hormone which has multiple roles in the body, in particular an autocrine function, which acts to promote skeletal health, and an endocrine function, which includes maintenance of serum calcium within a narrow range 121 . Since serum calcium homeostasis is of vital importance, the endocrine function can often operate to the detriment of the autocrine function 122 , which may account for the lack of clear results in vitamin D studies. Low serum calcium or phosphate triggers the synthesis of the vitamin D metabolite 1,25(OH)2D in kidney and bone, which in turn binds to the intestinal vitamin D receptor (VDR) and increases intestinal calcium 10, 123 , phosphorus 62, [67] [68] [69] and magnesium 94 absorption and renal reabsorption but also inhibits bone mineralisation 62 and upregulates bone resorption by facilitating osteoclast maturation to release calcium and phosphate, thereby increasing serum concentrations 11 . Active calcium absorption decreases when serum 25(OH) D concentration is <20nmol/L and consequently low calcium intake aggravates the consequences of vitamin D deficiency 123 . There is a decreasing ability with age to synthesise either 25(OH)D or 1,25(OH)2D as well as intestinal resistance to its action [124] [125] ; it appears that the optimal level of serum 25(OH) D for calcium absorption is >80nmol/l in postmenopausal women 126 . Vitamin D also has key roles in CV health, as indicated by the presence of the VDR in cardiomyocytes, vascular endothelial cells and VSMCs 127 . The principal source of vitamin D is sunlight on skin but foods such as egg yolk, offal, oily fish and shellfish also provide some intake, as well as fortified foods 124, 125 .
Ectopic calcification
There are no human intake studies with respect to CV calcification, probably because dietary vitamin D provides only a relatively small contribution to serum 25(OH)D. Animal studies, however, show that high vitamin D intake can induce CV calcification and impair endothelial function 128, 129 but they also show that a vitamin D deficient diet can induce an increase in calcified lesions [130] [131] [132] , indicating that both excess and deficiency are detrimental. Several epidemiological studies measuring serum 25(OH)D demonstrate an absence of association with presence or extent of CAC, MAC, cIMT, degree of carotid stenosis or mean arterial pressure 22, [133] [134] [135] , although patients with calcific aortic stenosis 136 and poor coronary collateral circulation 137 140 and with the calcification score in peripheral arterial disease 27 . Likewise with respect to serum 1,25(OH)2D, some studies show no association with CAC extent or progression 133, 141 , although in subjects at risk for CHD, serum 1,25(OH)2D was inversely correlated with the extent of calcification 142 .
There have been few intervention studies of vitamin D alone but in CKD patients the incidence of aortic calcification was significantly lower in treated patients 143 , while in heart failure, 4000IU/d for six months significantly improved the left ventricular ejection fraction 144 . Trials of vitamin D supplementation combined with calcium showed that up to 1000g/d calcium plus 400 IU/d vitamin D3 did not affect CAC scores or incidence of myocardial infarction (MI), CHD mortality or stroke in postmenopausal women [145] [146] , although there was an improvement in dyslipidaemia 147 ; this lack of result may be because the vitamin D dose was low. Nevertheless, although a 2011 systematic review found that serum 25(OH)D was not significantly associated with mortality, MI or stroke 148 , a metaanalysis of RCTs found that vitamin D supplementation for at least three years significantly decreased all-cause mortality 149 .
Bone
A 2006 systematic review and more recent studies of older adults showed that a vitamin D intake of ≥400 IU/d was associated with reduced bone loss [150] [151] [152] but with respect to fracture incidence, there appears to be little association with vitamin D intake 115 . Two large reviews found that in older adults, serum 25(OH)D was positively associated with BMD but there was inconsistent evidence for an association with fractures 153. In elderly postmenopausal women, those with serum 25(OH) D levels <50 nmol/L had increased fracture risk, bone loss and mortality, leading to recommendations that 50nmol/L should be the minimum level to ensure optimum bone health, below which supplementation is recommended at 800-1000IU/d but above Mechanism by which high serum phosphate (P) triggers release of FGF23 to lower serum P this threshold there was no clear evidence for additional benefit except in fragile elderly subjects, for whom serum 25(OH) D should be ≥75nmol/l 154 . Recent Korean studies confirm the positive association, which may not be linear 155 and indicate that BMD increases until 25(OH)D ≥70mmol/l in men and 50 nmol/l in women 156 . Ethnicity may have a bearing on the effect of vitamin D. A prospective study showed that higher 25(OH)D levels were associated with a lower risk of fracture in white women but a higher risk in black and Asian women and no association in Hispanic or Native American women 157 ; the NHANES study showed that mean 25(OH)D levels were highest in whites and lowest in blacks yet blacks had the highest BMD and whites had the lowest 158 .
When additionally considering calcium intake, the combination of higher vitamin D and calcium were associated with higher BMD in young adults 159 and reduced osteoporosis risk in postmenopausal women 47 , with the optimum dose for fracture reduction being 700-800IU/d vitamin D3 with 500-1200mg/d calcium 153 . Animal studies confirm that a diet deficient in calcium and vitamin D lowers BMD and increases urinary excretion of markers of bone resorption, not seen in calcium or vitamin D deficiency alone 160 . In humans, BMD and BMC loss and fracture risk were more consistently inversely associated with calcium intake and serum 25(OH)D taken together among all agegroups than either nutrient taken alone 150, 155 . Three recent reviews and meta-analyses of intervention studies found that vitamin D supplementation alone did not prevent fractures or increase BMD; the two reviews found a protective effect of vitamin D with calcium but results of the meta-analysis depend on the authors' 'futility boundary' [161] [162] [163] . A further meta-analysis found that in older adults, supplementation of 800IU/d could significantly reduce hip fractures and associated deaths over one year 164 .
Other multinutrient interactions
Lappe and Heaney point out that nutrient trials may fail because of inadequate attention to co-nutrient optimisation, including protein 165 . One of the most important mineral partnerships is that of calcium and phosphorus, with the calcium/phosphorus ratio in bone being 2.2:1 166 . An intake ratio of <1.0 was associated with nephrocalcinosis in rats but increasing the ratio to 1.3 inhibited calcification development 167 , while a low intake ratio increased osteoporosis risk in Koreans 168 and increased bone resorption markers 169 but a ratio of at least ≥0.74 benefited bone among younger females 87, 170 . Although phosphorus restriction increases serum ionised calcium 70 , phosphorus supplementation was also associated with decreased urinary calcium excretion 126, 171 , suggesting that calcium is retained to bind the phosphorus. There is also a strong interaction between calcium and magnesium, with low magnesium intake in animals increasing serum calcium, the calcium/phosphate ratio and calcium deposition in bone [172] [173] but with high calcium intake, serum and tissue magnesium was lower, suggesting decreased absorption 174 . High magnesium intake in calcium sufficiency, however, significantly improved all bone parameters compared to calcium insufficiency and when supplemented together, there was a significant improvement to all bone parameters 175 . There is competitive inhibition of gradientdependent intestinal absorption, not only between magnesium and calcium 67, 94 but also between magnesium and phosphorus provided calcium is adequate but magnesium absorption may increase at the expense of phosphorus when serum calcium is low 94 . Magnesium depletion is associated with increased serum ionised magnesium and calcium and decreased ionised phosphate 101, 102 . Magnesium also interacts with vitamin D, such that magnesium deficiency impairs the synthesis of 1,25(OH)2D even during dietary calcium deprivation 176 and can lead on to resistance to 1,25(OH)2D 177 .
Mechanisms
As well as vitamin D, additional regulators of CV calcification and bone mineralisation include parathyroid hormone (PTH) 178 and fibroblast growth factor 23 (FGF23), a phosphotonin secreted from bone, which appears to be a counter-regulatory hormone for vitamin D 179 . Figures 1-3 demonstrate how all three are involved in the regulation of serum calcium, phosphate and magnesium. Optimal PTH concentrations have been found when 25(OH)D ≥80nmol/l 180, 181 , while elevated FGF23 was associated with the CAC score in haemodialysis patients 182 and even among healthy subjects, the highest FGF23 quartile was associated with higher CAC scores and greater risk of heart failure and CHD 183 . Elevated serum phosphate can impair endothelial function, as evidenced by decreased vasodilatation, and may promote transdifferentation of VSMCs to osteoblastlike cells 71 .
Discussion
Although most studies show little association between calcium intake and CV calcification or BMD and fracture risk, the large study showing a positive correlation between higher intake and absence of AAC and the review showing an association between low intake and osteoporosis indicate that a higher intake is preferable. BMD studies indicate that this should be >800mg/d, with 1100mg/d for postmenopausal women, although larger doses were required for fracture prevention. Possibly the studies show a lack of association because even in the higher quartiles, intake is still too low. Serum calcium studies also generally show no association with CV calcification or bone, although a few show a positive association with AAC, but an association between serum calcium and bone would not be expected, since bone is a calcium reservoir to maintain serum levels. Bone studies also highlight the fact that ethnicity may distort results, which may be equally applicable to CV studies. There is no evidence that calcium supplementation increases CV risk; in fact calcium appears beneficial for prevention of CV events and mortality and can lower cholesterol and blood pressure.
Higher dietary and serum phosphorus may promote CV calcification even when serum phosphate is within normal range. Results of phosphorus intake and bone studies are mixed, possibly because phosphorus is necessary for healthy bone but the phosphoric acid in colas may pose a particular risk for bone loss in women. It appears that healthy individuals can adjust to a wide range of phosphorus consumption but have little adaptive ability for low calcium intake, indicating that the calcium/phosphorus intake ratio is more critical than the absolute phosphorus intake 184 ; any detrimental effect of high phosphorus intake can be negated by increasing calcium intake. Dietary and serum magnesium intake shows a strong inverse correlation with CV calcification, osteoporosis and bone loss, as well as with stroke incidence, cIMT and conventional rsk factors; CV calcification is minimised with intake in the quartile ranging from 384-669mg/d but this association may only apply to Caucasians. Calcification resulting from a low magnesium intake is particularly severe in animals when combined with high phosphorus intake. Although human trials are lacking, magnesium supplementation in animals significantly lowered CV calcification. In bone, magnesium supplementation increased BMD and improved markers of bone turnover.
Although human observational studies for vitamin D intake and CV calcification are lacking, animal studies show a U-shaped dose/response curve for intake, while bone studies found that intake of >/=400IU/d is required to reduce bone loss. Serum 25(OH)D is generally not correlated with CV calcification, except in CKD and other already-diagnosed conditions, where it is inversely associated, but in bone, serum 25(OH)D is positively associated with BMD. Intervention studies show reduced CV calcification in CKD, improved ventricular function in heart failure and lower mortality in longer term studies but no effect on CV calcification in healthy postmenopausal women, either alone or when accompanied by calcium, although the vitamin D dose was low (400IU/d). The vitamin D/calcium combination is beneficial to bone, however, provided the vitamin D dose is adequate. Bone studies indicate that supplementation of >/=800IU/d is required to bring serum 25(OH)D up to 50nmol/l in healthy adults or >/=75nmol/l in the fragile elderly. Ethnicity may again affect results, with higher 25(OH)D giving a higher fracture risk in black and Asian women. It is difficult to assess the CV or bone effects of vitamin D alone, since its predominant function is to maintain serum calcium homeostasis and it will do this to the detriment of bone or arteries if necessary; baseline serum calcium is seldom measured in these studies.
These studies highlight the interactions between the different micronutrients and point up the need for a calcium phosphorus intake in the ratio of >1 for bone health, which may also translate to arteries. Because of the competitive inhibition of absorption if intake of one mineral is imbalanced, it is important that adequate, but not excessive, intake of all bone minerals is maintained for both artery and bone health.
Conclusion
This review has firstly demonstrated that a mineral and vitamin D intake that is beneficial for bone is also generally protective against CV calcification. In principal this involves ensuring an adequate intake through diet or supplementation of each mineral and, in particular, supplementing sufficient calcium to balance any increased phosphorus intake to avoid upregulating PTH and to prevent a catabolic effect of vitamin D supplementation on bone to maintain serum calcium. These relationships may, however, not hold among African Americans and Asians. It has secondly shown the striking inter-relationship between the three bone minerals and vitamin D. This is particularly true with calcium, magnesium and vitamin D, where one can, to a certain extent, substitute for the other in the short term in maintaining bone health. Bone studies show limited effect when considering calcium and vitamin D separately but when supplemented together there is a significant protective effect. The competitive inhibition of absorption between all three minerals further emphasises that the diet should contain adequate levels of all three. The concern over the effect of supplemental calcium and CV events appears unnecessary since there is no evidence of any significant detrimental effects, whereas calcium supplementation may in fact be protective.
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